Advancing Gene Therapy Potency Testing with iPSC-Based Systems Available On Demand

https://www.workcast.com/register?cpak=9670327140636502&utm_campaign=MAL_HUM&utm_medium=email&_hsenc=p2ANqtz-9sAdSF6lNaIBZfPrFtDhEiU_BjrSz6d6FxkLRGFBCnJPJ2M4I2a1TyujMCr3OnUzkw9dIW_WW6e75JGngFI8sAH0j5aQ&_hsmi=390845464&utm_content=390845464&utm_source=hs_email Enabling AAV Gene Therapy Development: From Discovery to Release Gene therapy development demands models that truly reflect human biology. Ncardia’s iPSC-derived platforms provide scalable, disease-relevant systems to evaluate efficacy, toxicity and potency aligned with clinical needs. We collaborate with innovators across multiple disease areas, integrating iPSC-based screening into the developments of AAV. By applying human biology early – and keeping the ultimate goal of patient-ready therapies in sight – we help identify the most promising candidate therapy, reduce risk, and accelerate progress.